These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14990642)

  • 1. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.
    Labrie F; Champagne P; Labrie C; Roy J; Laverdière J; Provencher L; Potvin M; Drolet Y; Pollak M; Panasci L; L'Espérance B; Dufresne J; Latreille J; Robert J; Samson B; Jolivet J; Yelle L; Cusan L; Diamond P; Candas B
    J Clin Oncol; 2004 Mar; 22(5):864-71. PubMed ID: 14990642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
    J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts.
    Couillard S; Labrie C; Bélanger A; Candas B; Pouliot F; Labrie F
    J Natl Cancer Inst; 1998 May; 90(10):772-8. PubMed ID: 9605648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice.
    Couillard S; Labrie C; Gauthier S; Merand Y; Singh SM; Candas B; Labrie F
    Int J Cancer; 2000 Feb; 85(3):424-9. PubMed ID: 10652436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study.
    Veronesi A; Miolo G; Magri MD; Crivellari D; Scalone S; Bidoli E; Lombardi D
    BMC Cancer; 2010 May; 10():205. PubMed ID: 20470379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice.
    Luo S; Martel C; Sourla A; Gauthier S; Mérand Y; Belanger A; Labrie C; Labrie F
    Int J Cancer; 1997 Nov; 73(3):381-91. PubMed ID: 9359486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice.
    Gutman M; Couillard S; Labrie F; Candas B; Labrie C
    Cancer Res; 1999 Oct; 59(20):5176-80. PubMed ID: 10537294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800.
    Sourla A; Luo S; Labrie C; Bélanger A; Labrie F
    Endocrinology; 1997 Dec; 138(12):5605-17. PubMed ID: 9389549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
    Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD
    J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
    Münster PN; Buzdar A; Dhingra K; Enas N; Ni L; Major M; Melemed A; Seidman A; Booser D; Theriault R; Norton L; Hudis C
    J Clin Oncol; 2001 Apr; 19(7):2002-9. PubMed ID: 11283133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice.
    Couillard S; Gutman M; Labrie C; Bélanger A; Candas B; Labrie F
    Cancer Res; 1998 Jan; 58(1):60-4. PubMed ID: 9426058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
    Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
    J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
    Wang J; Jain S; Coombes CR; Palmieri C
    Breast J; 2009; 15(3):247-53. PubMed ID: 19645779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice.
    Couillard S; Gutman M; Labrie F; Candas B; Labrie C
    Cancer Res; 1999 Oct; 59(19):4857-63. PubMed ID: 10519396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.